Advertisement

Topics

Latest "Galectin Therapeutics" News Stories

08:29 EDT 25th September 2016 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 6,200+

Extremely Relevant

Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial

NORCROSS, Ga., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announces interim results from an exploratory, open-label, Phase 2a clinical trial with...


Roth resumes coverage of Galectin Therapeutics

Roth Capital Partners resumed coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and $3 price target. The stock closed at $1.52 on Friday. “In our opinion, Phase 1 data demonstrated Galectin’s GR-MD-02’s positive effect on NASH fibrosis biomarkers,” writes analyst Sa’ar Yaniv. “While we are expect that the 30-patient placebo-controlled Phase 2 study will [&...

Peter G. Traber, M.D., CEO and CMO of Galectin Therapeutics, to Speak on the Medical ...

Dr. Traber to speak on Galectin Therapeutics’ Development of GR-MD-02 for treatment of human disease Read more...


Enrollment in NASH-FX trial for advanced fibrosis, NASH complete

Galectin Therapeutics Inc. announced enrollment is complete for its phase 2 NASH-FX trial investigating GR-MD-02, a complex carbohydrate drug that targets galectin-3, for the treatment of nonalcoholic steatohepatitis and advanced fibrosis.The study, which will be led by Stephen A. Harrison, MD, FACP, FAASLD, professor of medicine at the Uniformed Services University of the Health Sciences, San Ant...

Psoriasis improvement not sufficient to continue says Galectin

Galectin Therapeutics Inc (NASDAQ:GALT) won’t pursue GR-MD-02 as a drug for psoriasis after patients in a small trial did not show the required improvement.   The drug developer added, however, that the results did give it encouragement for its liver fibrosis program, which is the drug’s primary focus.   Galectin started the small study after a patient taking the drug in a tr...

Relevant

Galectin completes enrollment for phase 2 trial of GR-MD-02 in fibrosis patients

Galectin Therapeutics has completed enrollment in its phase 2 clinical trial of GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis (stage 3).

RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways

Galectin-3 And Cardiac Troponins Reference Values Determined

Galectin-3 is a unique member of chimera type galectins and is involved in a large number of disease processes and...

A Major Catalyst Awaits Galectin Therapeutics Next Week

Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of ...

Read more...

Galectin completes patient recruitment in NASH trial

Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX trial. The company expects to report the topline results of the trial in December 2017. “We are pleased that patient recruitment in our NASH-CX trial was completed ahead of our original […]

Unexpected Properties of Galectin-3

The new study examines the biomechanics of galectin-3's interaction with glycosaminoglycans (GAG) and proteoglycans. Tarun Dam, an associate professor of chemistry at Michigan Technological University, led the study. The other co-authors of the paper are graduate students Melanie Talaga, Ni Fan, ...

BRIEF-Galectin Therapeutics completes enrollment in mid stage trial for NASH drug

* Completion of enrollment in phase 2 clinical trial with GR-MD-02 in patients with NASH with advanced fibrosis

Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update

Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September Australian patent allowance strengthens global intellectual property franchise NORCROSS, Ga., Aug. 09, 2016 (GLOBE NEWSWIRE) Read more...

BRIEF-Galectin Therapeutics posts results from extended psoriasis clinical trial - SEC Filing

* Says announces results from 12-week extension of phase 2A psoriasis clinical trial - SEC Filing

Sugar-binding protein galectin-9 found to be a new weapon to cure HIV

The ultimate impediment to a cure for HIV infection is the presence of latent, HIV-infected cells, which can reawaken and produce new virus when antiretroviral drug therapy is stopped. These latent, HIV-infected cells are untouched by antiretroviral therapy and are unseen by the immune system. Moving medicine closer to a cure for HIV, scientists at Blood Systems Research Institute (BSRI), the Univ...

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

Galectin-4 (LGALS4)

Patient sample, cell culture and mouse studies suggest inhibiting

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation

Cell surface galectin-3 defines a subset of chemoresistant gastrointestinal tumor-initiating cancer cells with heightened stem cell characteristics

Sugar-binding protein galectin-9 could be new weapon to fight HIV

The ultimate impediment to a cure for HIV infection is the presence of latent, HIV-infected cells, which can reawaken and produce new virus when antiretroviral drug therapy is stopped.

Seres Therapeutics, Emulate collaborate to support development of novel microbiome therapeutics

Seres Therapeutics, a microbiome therapeutics platform company, and Emulate, a private firm commercializing the Organs-on-Chips technology, announced a new collaboration.

As big pharma moves in, biotech Galectin looks to stake claim to NASH market

NASH, a fatty liver disease, has grown in prevalence, with some saying it will replace hepatitis C as the main cause of liver transplantation by 2020. 

BIND Therapeutics says Pfizer’s $40 million bid for its assets is the winner

US biotech firm BIND Therapeutics, a developer of targeted and programmable therapeutics called Accurins,…


Quick Search
Advertisement
 

News Quicklinks